Nurzhamal Akhmadyar

Dr. Nurzhamal Akhmadyar

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
Yerke SuleimenovaYerke Suleimenova
Yerke Suleimenova
Indira KaribayevaIndira Karibayeva
Indira Karibayeva
Шнара СветлановаШнара Светланова
Шнара Светланова
Nurzhamal AkhmadyarNurzhamal Akhmadyar
Nurzhamal Akhmadyar
DBDinagul Bayesheva
Dinagul Bayesheva
ABAida Bolatbek
Aida Bolatbek
Background/Objectives: Rotavirus remains a major cause of acute gastroenteritis among children under five years of age, particularly in regions with heterogeneous vaccine implementation. In Central Asia, differences in the timing and coverage of rotavirus vaccination may influence circulating genotype patterns, yet regional evidence remains fragmented. Methods: A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD420251274198). Electronic databases (PubMed, Web of Science, ScienceDirect, and Google Scholar) were searched without date restrictions. Studies reporting laboratory-confirmed rotavirus infection and genotype distribution among children under five years in Central Asia were included. Random-effects meta-analysis of proportions was performed to estimate the pooled genotype proportions among rotavirus-positive children, with subgroup analyses comparing the before and after vaccine introduction periods. Results: Six studies (ten before vaccine introduction strata and four after vaccine introduction strata; N = 1713 rotavirus-positive children) were included. A significant decline in the G1P[8] genotype was observed following vaccine introduction, with pooled prevalence decreasing from 0.468 (95% CI: 0.363–0.577) to 0.068 (95% CI: 0.034–0.133) (p < 0.001). In contrast, G2P[4] increased from 0.134 to 0.485 (p < 0.001), while G9P[4] and G9P[8] also increased significantly. G3P[8] and mixed genotypes declined, whereas G4P[8], G12P[8], and untypable strains showed no statistically significant subgroup differences. Substantial heterogeneity was observed (I2 > 90%), and evidence certainty was very low for all genotype outcomes. Conclusions: The available evidence suggests that rotavirus genotype distribution among children under five in Central Asia may have changed after vaccine introduction, with lower pooled proportions of G1P[8] and higher proportions of selected heterotypic genotypes in after vaccine introduction strata. Strengthened molecular surveillance using standardized genotyping protocols is needed to determine whether these patterns represent sustained genotype replacement or temporal fluctuation. These estimates are based on a small, heterogeneous evidence base with very low certainty and should be considered hypothesis-generating rather than confirmatory of a causal vaccine effect.

16 October 2026 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
Nurzhamal AkhmadyarNurzhamal Akhmadyar
Nurzhamal Akhmadyar
BKBulat Kupenov
Bulat Kupenov
BKBerik Konakbay
Berik Konakbay
SBSaule Burkitbayeva
Saule Burkitbayeva
ZZZhandaulet Zhaxylykuly
Zhandaulet Zhaxylykuly
Introduction: Multi-year hospital-level data on drug expenditure in Kazakhstan are scarce, although antimicrobial resistance and the growing use of high-cost biologics require expenditure monitoring tools. This study aimed to quantify four-year trends in drug expenditure, formulary structure and antibiotic spending in a multidisciplinary tertiary care hospital. Methods: Annual pharmacy dispensing ledgers for 2022–2025 were analyzed retrospectively. Each item was assigned an International Nonproprietary Name and an Anatomical Therapeutic Chemical code. ABC analysis and vital, essential and non-essential classification were performed by nonproprietary name, and antibacterials were mapped to the World Health Organization Access, Watch and Reserve groups. Expenditure was normalized per bed-day. Results: The number of nonproprietary names dispensed decreased from 194 to 172, whereas expenditure increased by 40.6% to 523.8 million Kazakhstani tenge and expenditure per bed-day by 35.1%. The share of immunosuppressants rose from 2.9% to 22.8%; ustekinumab and vedolizumab accounted for 20.3% of expenditure in 2025. Group A comprised 15.1–19.1% of names and 80.0–80.8% of expenditure; no non-essential medicine entered group A, but non-essential expenditure increased to 1.9% in 2025. Antibacterial expenditure rose by 66.6% in 2025; Watch agents accounted for 75.5–78.1% and Reserve agents for 10.3–14.4% of antibacterial spending. Conclusions: Formulary contraction coincided with a shift of the budget toward biologics and Watch and Reserve antibiotics. The findings are limited by the single-center design, nominal prices and the absence of consumption metrics based on defined daily doses; expenditure-based Access, Watch and Reserve signals should be combined with such metrics in multicenter studies. Keywords: Drug costs; Drug utilization; Anti-bacterial agents; Antimicrobial Stewardship; Tertiary Care Centers; Formulary management;